Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients

Authors: Li Zhang, Dan Liu, Lei Li, Dan Pu, Ping Zhou, Yuting Jing, He Yu, Yanwen Wang, Yihan Zhu, Yanqi He, Yalun Li, Shuang Zhao, Zhixin Qiu, Weimin Li

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The roles of carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21-1) and neuron-specific enolase (NSE) in metastases occurrence and poor diagnosis in specific histological classifications of lung cancer need further exploring. In this study, we investigated relationship between elevated levels of three biomarkers of CEA, CYFRA21-1 and NSE (individually and in combination) and metastasis, survival status and prognosis in lung cancer patients.

Methods

Eight hundred and sixty eight lung cancer patients including adenocarcinoma (ADC, N = 445), squamous cell carcinoma (SCC, N = 215), small cell lung cancer (SCLC, N = 159) and other types (N = 49) were categorized into negative, moderate and high groups according to serum levels of biomarkers, and were then categorized into negative, single, double and triple groups according to any positive combination of three biomarkers. The cutoff values of three biomarkers for groupings were developed on the training group (N = 432) and verified in a validation group (N = 436). Clinical and laboratory characteristics were then assessed for correlation with occurrence of metastasis, survival status and prognosis between the two groups. Further correlation analyses were also conducted by different subtypes (ADC, SCC and SCLC) and tumor stages (I + II, III and IV) of lung cancers.

Results

The consistent results between training and validation group confirmed the rationality of grouping methods. CYFRA21-1 levels had stronger association with metastases and survival status than CEA and NSE in all lung cancer patients. When stratified by subtypes, these significances only existed in ADC patients for CYFRA21-1. Cox regression analyses showed that CYFRA21-1 and NSE were independent prognostic factors for lung cancer patients. However, only CYFRA21-1 was an independent prognostic factor in ADC and SCLC patients subtypes. Cox-regression results also indicated that CYFRA21-1 could act as independent prognostic factor in different stages (I + II, III and IV) of lung cancer.

Conclusion

CYFRA21-1 was more important in metastasis occurrence and in predicting poor prognosis in lung cancer patients than CEA, NSE and positive numbers of biomarkers.
Appendix
Available only for authorised users
Literature
2.
go back to reference American cancer society. Lung cancer (non-small cell). 2012. p. 1–68. American cancer society. Lung cancer (non-small cell). 2012. p. 1–68.
3.
go back to reference Patz JE, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25:5578–83.CrossRefPubMed Patz JE, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25:5578–83.CrossRefPubMed
4.
go back to reference Sandeler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Eng J Med. 2006;335:2542–50.CrossRef Sandeler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Eng J Med. 2006;335:2542–50.CrossRef
5.
go back to reference Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGR. N Eng J Med. 2010;362:2380–8.CrossRef Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGR. N Eng J Med. 2010;362:2380–8.CrossRef
6.
go back to reference Mulshine JL, D’Amico TA. Issues with implementing a high-quality lung cancer screening program. CA Cancer J Clin. 2015;64:351–63.CrossRef Mulshine JL, D’Amico TA. Issues with implementing a high-quality lung cancer screening program. CA Cancer J Clin. 2015;64:351–63.CrossRef
7.
go back to reference Johnson DH, Schiller JH. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32:1–10.CrossRef Johnson DH, Schiller JH. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32:1–10.CrossRef
8.
go back to reference Sun N, Chen ZL, Tan FW, et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin Can Res. 2013;19:5136–45.CrossRef Sun N, Chen ZL, Tan FW, et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin Can Res. 2013;19:5136–45.CrossRef
9.
go back to reference Arnold JN, Saldova R, Galligan MC, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011;10:1755–64.CrossRefPubMed Arnold JN, Saldova R, Galligan MC, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011;10:1755–64.CrossRefPubMed
10.
go back to reference Feng Q, Yu M, Kiviat NB. Molecular biomarkers for the cancer detection in blood and bodily fluids. Crit Rev Clin Lab Sci. 2006;43:497–560.CrossRefPubMed Feng Q, Yu M, Kiviat NB. Molecular biomarkers for the cancer detection in blood and bodily fluids. Crit Rev Clin Lab Sci. 2006;43:497–560.CrossRefPubMed
11.
go back to reference Hsu WH, Huang CS, Hsu HS, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann ThroacSurg. 2007;83:419–24.CrossRef Hsu WH, Huang CS, Hsu HS, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann ThroacSurg. 2007;83:419–24.CrossRef
12.
go back to reference Rastel D, Ramaioli A, Cornillie F, et al. CYFRA 21–1, a sensitive and specific new tumor marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21–1 multicentre study group. Eur J Cancer. 1994;30A:601–6.CrossRefPubMed Rastel D, Ramaioli A, Cornillie F, et al. CYFRA 21–1, a sensitive and specific new tumor marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21–1 multicentre study group. Eur J Cancer. 1994;30A:601–6.CrossRefPubMed
13.
go back to reference Li J, Dai CH, Chen P, et al. Survival and prognostic factors in small cell lung cancer. Med Oncol. 2010;1:73–81.CrossRef Li J, Dai CH, Chen P, et al. Survival and prognostic factors in small cell lung cancer. Med Oncol. 2010;1:73–81.CrossRef
14.
go back to reference Jung M, Kim SH, Hong S, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J. 2012;53:931–9.CrossRefPubMedPubMedCentral Jung M, Kim SH, Hong S, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J. 2012;53:931–9.CrossRefPubMedPubMedCentral
15.
go back to reference Chu XY, Hou XB, Song WA, et al. Diagnostic values of SCC, CEA, CYFRA21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther. 2011;11:995–1000.CrossRefPubMed Chu XY, Hou XB, Song WA, et al. Diagnostic values of SCC, CEA, CYFRA21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther. 2011;11:995–1000.CrossRefPubMed
16.
go back to reference Hur J, Lee HJ, Nam JE, et al. Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer. BMC Cancer. 2012;12:392.CrossRefPubMedPubMedCentral Hur J, Lee HJ, Nam JE, et al. Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer. BMC Cancer. 2012;12:392.CrossRefPubMedPubMedCentral
17.
go back to reference Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (Seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007;2:706–14.CrossRefPubMed Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (Seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007;2:706–14.CrossRefPubMed
18.
go back to reference Wang P, Piao YZ, Zhang XH, et al. The concentration of CYFRA21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer. Can Biomark. 2013;13:123–30.CrossRef Wang P, Piao YZ, Zhang XH, et al. The concentration of CYFRA21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer. Can Biomark. 2013;13:123–30.CrossRef
19.
go back to reference Park SY, Lee JG, Kim J, et al. Preoperative serum CYFRA21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 2013;79:156–60.CrossRefPubMed Park SY, Lee JG, Kim J, et al. Preoperative serum CYFRA21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 2013;79:156–60.CrossRefPubMed
20.
go back to reference Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–43.CrossRefPubMed Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–43.CrossRefPubMed
21.
go back to reference Tomita M, Shimizu T, Ayabe T, et al. Prognostic significance of tumor marker index based on preoperative CEA and CYFRA21-1 in non-small cell lung cancer. Anticancer Res. 2010;30:3009–12. Tomita M, Shimizu T, Ayabe T, et al. Prognostic significance of tumor marker index based on preoperative CEA and CYFRA21-1 in non-small cell lung cancer. Anticancer Res. 2010;30:3009–12.
22.
go back to reference Molina R, AugeJM FX, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA21-1 and NSE in patients with lung cancer. Anticancer Res. 2005;25:1773–8.PubMed Molina R, AugeJM FX, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA21-1 and NSE in patients with lung cancer. Anticancer Res. 2005;25:1773–8.PubMed
23.
go back to reference Lee DS, Kim YS, Jung SL, et al. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumor Biol. 2013;33:1065–73.CrossRef Lee DS, Kim YS, Jung SL, et al. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumor Biol. 2013;33:1065–73.CrossRef
24.
go back to reference Okamura K, Takayama K, Izumi M, et al. Diagnostic value of CEA and CYFRA21-1 tumor markers in primary lung cancer. Lung Cancer. 2013;80:45–9.CrossRefPubMed Okamura K, Takayama K, Izumi M, et al. Diagnostic value of CEA and CYFRA21-1 tumor markers in primary lung cancer. Lung Cancer. 2013;80:45–9.CrossRefPubMed
25.
go back to reference Kosacka M, Jankowska R. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21–1 levels in non-small cell lung cancer. Pol Arch Med Wewn. 2009;119:33–7.PubMed Kosacka M, Jankowska R. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21–1 levels in non-small cell lung cancer. Pol Arch Med Wewn. 2009;119:33–7.PubMed
26.
go back to reference Edelman MJ, Hodgson L, Rosenblatt PY, et al. CYFRAY 21–1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: GALGB 150304. J ThoracOncol. 2012;7:649–54. Edelman MJ, Hodgson L, Rosenblatt PY, et al. CYFRAY 21–1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: GALGB 150304. J ThoracOncol. 2012;7:649–54.
27.
go back to reference Barlesi F, Tchouhadjian C, Doddoli C, et al. CYFRA 21–1 level predicts survival in non-small cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer. 2005;92:13–4.CrossRefPubMed Barlesi F, Tchouhadjian C, Doddoli C, et al. CYFRA 21–1 level predicts survival in non-small cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer. 2005;92:13–4.CrossRefPubMed
28.
go back to reference Petrovic M, Bukumiric Z, Zdravkoivc V, et al. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small cell lung cancer. Med Oncol. 2014;31:823.CrossRefPubMed Petrovic M, Bukumiric Z, Zdravkoivc V, et al. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small cell lung cancer. Med Oncol. 2014;31:823.CrossRefPubMed
Metadata
Title
The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients
Authors
Li Zhang
Dan Liu
Lei Li
Dan Pu
Ping Zhou
Yuting Jing
He Yu
Yanwen Wang
Yihan Zhu
Yanqi He
Yalun Li
Shuang Zhao
Zhixin Qiu
Weimin Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3070-6

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine